Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06004661
- Locations
- 🇺🇸
Mount Sinai Hosp School of Med, New York, New York, United States
🇪🇸Novartis Investigative Site, El Palmar, Murcia, Spain
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)
- Conditions
- Acute Kidney Injury Due to Sepsis
- Interventions
- Biological: TIN816 70 mg lyophilisate powderOther: Placebo
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT05996835
- Locations
- 🇺🇸
UC San Francisco Medical Center, San Francisco, California, United States
🇺🇸Stanford Healthcare, Stanford, California, United States
🇺🇸Emory Johns Creek Hospital, Johns Creek, Georgia, United States
A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT05985915
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Advanced Medical Research, La Palma, California, United States
🇺🇸Medvin Clinical Research, Van Nuys, California, United States
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
- Conditions
- BRAF Positive Metastatic Melanoma
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1961
- Registration Number
- NCT05984615
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1093
- Registration Number
- NCT05982886
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05983198
- Locations
- 🇫🇷
Novartis Investigative Site, Vandoeuvre Les Nancy, France
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 348
- Registration Number
- NCT05976243
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Acuro Research Inc, Little Rock, Arkansas, United States
🇺🇸Kern Research, Bakersfield, California, United States
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
- Conditions
- Pancreatic Ductal AdenocarcinomaGlioblastoma MultiformeGastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT05977322
- Locations
- 🇨🇭
Novartis Investigative Site, Geneve 14, Switzerland
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1125
- Registration Number
- NCT05976230
- Locations
- 🇯🇵
Novartis Investigative Site, Yamaguchi, Japan
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204691
- Registration Number
- NCT05974345
- Locations
- 🇫🇷
Novartis Investigative Site, Rueil-Malmaison, France